Sunbeam Capital Management LLC Buys New Shares in Johnson & Johnson $JNJ

Sunbeam Capital Management LLC bought a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 1,574 shares of the company’s stock, valued at approximately $240,000.

A number of other institutional investors also recently modified their holdings of the stock. KLP Kapitalforvaltning AS lifted its position in shares of Johnson & Johnson by 3.1% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 1,117,314 shares of the company’s stock valued at $170,670,000 after acquiring an additional 33,700 shares during the period. Bingham Private Wealth LLC raised its holdings in shares of Johnson & Johnson by 123.7% in the second quarter. Bingham Private Wealth LLC now owns 8,728 shares of the company’s stock valued at $1,333,000 after purchasing an additional 4,827 shares during the last quarter. RMG Wealth Management LLC purchased a new stake in shares of Johnson & Johnson in the second quarter valued at about $457,000. Seamount Financial Group Inc. increased its holdings in Johnson & Johnson by 7.3% during the second quarter. Seamount Financial Group Inc. now owns 4,821 shares of the company’s stock worth $736,000 after buying an additional 327 shares during the last quarter. Finally, Drake & Associates LLC increased its holdings in Johnson & Johnson by 46.1% during the second quarter. Drake & Associates LLC now owns 21,758 shares of the company’s stock worth $3,324,000 after buying an additional 6,862 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.5%

Shares of JNJ opened at $189.75 on Thursday. The firm has a market cap of $456.98 billion, a price-to-earnings ratio of 20.29, a PEG ratio of 2.41 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $190.22. The firm has a 50 day moving average price of $177.49 and a 200-day moving average price of $163.37.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same period in the previous year, the business posted $2.82 EPS. The business’s quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is 55.61%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. HSBC raised their price objective on shares of Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. Royal Bank Of Canada raised their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research report on Thursday, July 17th. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their target price for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Finally, Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $189.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.